#### 1 Examining Longitudinal Markers of Bladder Cancer Recurrence Through a Semi-

#### 2 Autonomous Machine Learning System for Quantifying Specimen Atypia from Urine 3 Cytology

- 4 Joshua J. Levy PhD<sup>1,2,3,4,\*</sup>, Natt Chan MS<sup>4</sup>, Jonathan D. Marotti MD<sup>1,5</sup>, Nathalie J. Rodrigues
- MD<sup>1</sup>, A. Aziz O. Ismail MD<sup>1,6</sup>, Darcy A. Kerr MD<sup>1,5</sup>, Edward J. Gutmann MD, AM<sup>1,5</sup>, Ryan E. 5
- Glass MD<sup>7</sup>, Caroline P. Dodge<sup>8</sup>, Arief A. Suriawinata MD<sup>1,5</sup>, Brock Christensen PhD<sup>3,9,10</sup>, 6
- 7 Xiaoving Liu MD<sup>1,5,†</sup>, Louis J. Vaickus MD, PhD<sup>1,5,†</sup>
- 8 1. Emerging Diagnostic and Investigative Technologies, Department of Pathology and 9 Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, 03766
- 10 2. Department of Dermatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, 03766
- 11 3. Department of Epidemiology, Dartmouth College Geisel School of Medicine, Hanover, 12 NH, 03756
- 13 4. Program in Quantitative Biomedical Sciences, Dartmouth College Geisel School of 14 Medicine, Hanover, NH, 03756
- 5. Dartmouth College Geisel School of Medicine, Hanover, NH, 03756 15
- 16 6. White River Junction VA Medical Center, White River Junction, VT, 05009
- 17 7. UPMC East, Pittsburg, PA, 15146
- 18 8. Cambridge Health Alliance, Cambridge, MA, 02139
- 19 9. Department of Molecular and Systems Biology, Dartmouth College Geisel School of 20 Medicine, Hanover, NH, 03756
  - 10. Department of Community and Family Medicine, Dartmouth College Geisel School of Medicine, Hanover, NH, 03756
- 23 \* To whom correspondence should be addressed: joshua.j.levy@dartmouth.edu
- 24 <sup>†</sup> Authors contributed equally

#### 26 **Author Contributions**

- JL and LV: conceptualization, formal analysis, funding acquisition, investigation, methodology, 27
- 28 project administration, resources, software, supervision, validation, visualization, writing -
- 29 original draft; XL, JM, DK, EG, RG, CD, LV, NR: data curation; all authors: writing - review
- 30 and editing
- 31

21

22

25

#### 32 **Conflict of Interest**

- 33 None to disclose.
- 34

#### 35 **Funding Sources**

36 JL is supported by NIH subawards P20GM104416 and P20GM130454

#### 37 38 Precis

- 39 This study used AutoParis-X, a machine learning tool, to extract imaging features from urine
- 40 cytology exams to predict recurrence risk in bladder cancer patients. The results demonstrate that
- 41 quantitative features of urine specimen atypia can predict recurrence as well or better than
- 42 traditional cytological/histological assessments alone and can potentially complement traditional
- 43 methods of assessment in screening programs pending further development and validation of
- 44 computational methods which leverage multiple longitudinal cytology exams.

## 45 Abstract

46 Urine cytology (UC) is generally considered the primary approach for screening for recurrence

- of bladder cancer. However, it is currently unclear how best to use cytological exams themselves
   for the assessment and early detection of recurrence, beyond identifying a positive finding which
- 49 requires more invasive methods to confirm recurrence and decide on therapeutic options. As
- 50 screening programs are frequent, and can be burdensome, finding quantitative means to reduce
- 51 this burden for patients, cytopathologists and urologists is an important endeavor and can
- 52 improve both the efficiency and reliability of findings. Additionally, identifying ways to risk-
- 53 stratify patients is crucial for improving quality of life while reducing the risk of future
- 54 recurrence or progression of the cancer. In this study, we leveraged a computational machine
- 55 learning tool, AutoParis-X, to extract imaging features from UC exams longitudinally to study
- 56 the predictive potential of urine cytology for assessing recurrence risk. This study examined how
- 57 the significance of imaging predictors changes over time before and after surgery to determine
- 58 which predictors and time periods are most relevant for assessing recurrence risk. Results
- 59 indicate that imaging predictors extracted using AutoParis-X can predict recurrence as well or
- 60 better than traditional cytological / histological assessments alone and that the predictiveness of
- 61 these features is variable across time, with key differences in overall specimen atypia identified
- 62 immediately before tumor recurrence. Further research will clarify how computational methods
- 63 can be effectively utilized in high volume screening programs to improve recurrence detection
- 64 and complement traditional modes of assessment.

#### 66 Introduction

Urothelial carcinoma ranks ninth worldwide in cancer incidence as the seventh most common 67 malignancy in men and seventeenth in women <sup>1–3</sup>. In the United States, urinary bladder cancer 68 69 (UBC) is the fourth most common cancer in men and tenth in women. Of urothelial cancer cases, 70 most are forms of UBC at approximately 90%, while upper tract urothelial carcinomas account 71 for 5-10% of malignancies <sup>4-7</sup>. The 5-year relative survival rates for UBC patients range from 72 97% at Stage I to 22% at Stage IV<sup>8-11</sup>. Most UBC incidences (75-85%) are non-muscle invasive 73 (NMIBC) at first diagnosis, of which 70% register as pTa (noninvasive papillary carcinoma), 74 20% as pT1, and 10% as carcinoma in situ (CIS) lesions, pTis. The prognosis of NMIBC is 75 generally favorable, although 30-80% of cases will recur and 1-45% of cases will progress to muscle invasion within five years <sup>12</sup>. As a result, NMIBC is treated as a chronic disease with a 76 77 variety of oncological outcomes that require frequent follow-ups for monitoring and repeated treatments, giving it the highest cost-per-patient from diagnosis to death of all cancers <sup>13</sup>. 78

79

80 The standard approach to patients with symptoms suggestive of UBC involve a combination of 81 urine cytology, cystoscopy (potentially with tissue biopsy(s)), and immunocytochemical and molecular studies with longitudinal follow-up for negative and atypical findings <sup>14–23</sup>. After a 82 83 positive diagnosis of UBC, urine cytology remains an essential longitudinal monitoring tool for 84 patients. However, urine cytology suffers from susceptibility to issues such as specimen quality, 85 inter/intra-observer variability, and 'hedging' towards atypical diagnosis, making it a semiqualitative assessment and vulnerable to individual biases <sup>24–28</sup>. Such factors restrict the 86 87 predictive value of urine cytology therefore increasing reliance on invasive cystoscopy.

88

89	Cytology specimens have historically been tedious to screen, in part due to the sheer volume of
90	specimens to examine, resulting from regular periodic follow-up and the highly variable
91	specimen cellularity. While positive and negative urine cytology specimens are easier to classify,
92	atypical and suspicious urine samples are more challenging and feature poor inter-observer
93	reproducibility. In recent years, The Paris System for Reporting Urinary Cytology (TPS),
94	published in 2016 and updated in 2022, has established itself as the widely accepted
95	classification system for UBC screening <sup>24,29,30</sup> . It devised to tackle the challenges posed by
96	atypical urines and improve reproducibility <sup>31,32</sup> . Computer algorithms such as the AutoParis
97	system were designed to ameliorate many of these screening challenges/burdens to make urine
98	cytology quantitative by employing machine learning techniques that can mimic rapid
99	examination with TPS criteria <sup>33–39</sup> . AutoParis, and its latest iteration, AutoParis-X, calculate an
100	Atypia Burden Score (ABS) after cross-tabulating several cellular and cluster-level subjective
101	and objective indicators of atypia <sup>34,40</sup> .

102

As bladder cancer recurrence is a significant concern for patients and healthcare providers,
various methods have been developed to predict and monitor the likelihood of recurrence. While
computer-aided assessment of the primary tumor has been shown to be predictive of likelihood
for recurrence <sup>41,42</sup>, this examination presents only a snapshot in time, which could be augmented
by repeated urine cytology exams <sup>43–45</sup>. However, there is currently little to no research on how
repeat urine cytology exams can be leveraged to derive longitudinal markers of recurrence <sup>46–49</sup>.

110 Assessing the prognostic capacity of imaging predictors in urine specimens for the treatment of

111 bladder cancer can have great benefits in reducing clinician workload, improving reproducibility,

112	reduci	ng human error, and lowering treatment cost, in part because cytology predictors can serve
113	as an '	'early warning system" for which patients require the most attention/care <sup>50</sup> . In this specific
114	work,	we investigate the potential of using machine learning from urine cytology in predicting
115	recurre	ence among a cohort of patients <sup>40</sup> .
116		
117	Metho	ods
118	Metho	ods Overview
119	In this	section, we summarize the approaches taken to assess the ability to predict time to
120	recurre	ence from image-derived UC predictors:
121	1.	Retrospective review identifies cases with varying follow-up and number of recurrences.
122	2.	Slide images are scanned (Figure 1A) and imaging predictors are extracted from each
123		whole-slide image (WSI) (Figure 1B) using AutoParis-X, which improved upon
124		techniques introduced by AutoParis <sup>34,40</sup> .
125	3.	Fixed predictors are constructed by aggregating quantitative cytological exam
126		information across distinct collection periods (i.e., collection time; Figure 1C); Cox
127		proportional hazards models are developed to predict recurrence risk and compare with
128		manual assessments (UC Class) and tumor grade/stage/type (histology) <sup>51,52</sup> .
129	4.	Dynamic predictors are constructed by utilizing the imaging predictors of each individual
130		cytology exam; these predictors vary with time (time-varying covariates) and their effects
131		are reported across different time periods through time-varying coefficient Cox models
132		( <b>Figure 1D</b> ) <sup>53,54</sup> .
133	5.	Models are interpreted by regression coefficients (i.e., hazard ratios), concordance
134		statistics, and clustering time series, which shows how imaging predictors vary across

135 time for low-risk / high-risk patients with commensurate statistical modeling (e.g.,

137



138

139 Figure 1: Study Overview: A) UC images are acquired for patients across the study period and 140 are processed using **B**) AutoParis-X, which extracts imaging predictors, e.g., ABS; **C**) Imaging 141 predictors are aggregated across collection periods to form *fixed predictors* which are then used to assess time-to-recurrence using Cox models; D) Imaging predictors were also studied 142 143 dynamically considering results/extracted features from individual tests and their recurrence 144 potential; risk of recurrence was also studied within specific time periods to demonstrate how the importance of these predictors varies with time; E) Scatterplots for two patients with time from 145 146 the first positive primary versus the Atypia Burden Score as assessed using AutoParis-X; points 147 were labeled by the UC categories assigned through manual examination of urine cytology

148

## 149 Specimen Collection

- 150 A total of 1,259 urine specimens collected from 135 bladder cancer patients at Dartmouth-
- 151 Hitchcock Medical Center between 2008 and 2019 were retrieved, after institutional review
- 152 board approval. The median number of specimens per patient was 8, with an interquartile range
- 153 of [8-13] (Figure 1A). Several patients were omitted due to insufficient follow-up or significant
- 154 left-censoring which precluded assessment. The specimens were prepared using ThinPrep®

<sup>57</sup> . They were then scanned with a Leica Aperio-AT2 scanner at 40x resolution, resulting in fur- resolution SVS files (70% quality JPEG compression) representing whole slide images. The slides were manually focused on a single plane during scanning, without the use of z-stacking Patient and slide-level characteristics from the retrospective cohort are provided in <b>Table 1</b> . A slides were evaluated by five cytopathologists to provide diagnoses based on The Paris Syster criteria (negative, atypical, suspicious, positive). Separately, patient characteristics, e.g., hematuria, prior treatments (e.g., BCG– Bacillus Calmette-Guerin or mitomycin) were record in a secure database <sup>59</sup> . Time to recurrence was determined as indexed from the date of the fir positive primary tumor as determined through histological examination. Individuals were righ censored based on last known histological follow-up <sup>60</sup> .	155	(Hologic, Marlborough MA) and Papanicolaou staining before being examined microscopically
<ul> <li>resolution SVS files (70% quality JPEG compression) representing whole slide images. The</li> <li>slides were manually focused on a single plane during scanning, without the use of z-stacking</li> <li>Patient and slide-level characteristics from the retrospective cohort are provided in Table 1. A</li> <li>slides were evaluated by five cytopathologists to provide diagnoses based on The Paris Syster</li> <li>criteria (negative, atypical, suspicious, positive). Separately, patient characteristics, e.g.,</li> <li>hematuria, prior treatments (e.g., BCG– Bacillus Calmette-Guerin or mitomycin) were record</li> <li>in a secure database <sup>59</sup>. Time to recurrence was determined as indexed from the date of the firm</li> <li>positive primary tumor as determined through histological examination. Individuals were right</li> <li>censored based on last known histological follow-up <sup>60</sup>.</li> </ul>	156	<sup>57</sup> . They were then scanned with a Leica Aperio-AT2 scanner at 40x resolution, resulting in full-
<ul> <li>slides were manually focused on a single plane during scanning, without the use of z-stacking</li> <li>Patient and slide-level characteristics from the retrospective cohort are provided in Table 1. A</li> <li>slides were evaluated by five cytopathologists to provide diagnoses based on The Paris Syster</li> <li>criteria (negative, atypical, suspicious, positive). Separately, patient characteristics, e.g.,</li> <li>hematuria, prior treatments (e.g., BCG– Bacillus Calmette-Guerin or mitomycin) were record</li> <li>in a secure database <sup>59</sup>. Time to recurrence was determined as indexed from the date of the first</li> <li>positive primary tumor as determined through histological examination. Individuals were right</li> <li>censored based on last known histological follow-up <sup>60</sup>.</li> </ul>	157	resolution SVS files (70% quality JPEG compression) representing whole slide images. The
Patient and slide-level characteristics from the retrospective cohort are provided in <b>Table 1</b> . A slides were evaluated by five cytopathologists to provide diagnoses based on The Paris System criteria (negative, atypical, suspicious, positive). Separately, patient characteristics, e.g., hematuria, prior treatments (e.g., BCG– Bacillus Calmette-Guerin or mitomycin) were record in a secure database <sup>59</sup> . Time to recurrence was determined as indexed from the date of the firm positive primary tumor as determined through histological examination. Individuals were right censored based on last known histological follow-up <sup>60</sup> .	158	slides were manually focused on a single plane during scanning, without the use of z-stacking <sup>58</sup> .
slides were evaluated by five cytopathologists to provide diagnoses based on The Paris Syster criteria (negative, atypical, suspicious, positive). Separately, patient characteristics, e.g., hematuria, prior treatments (e.g., BCG– Bacillus Calmette-Guerin or mitomycin) were record in a secure database <sup>59</sup> . Time to recurrence was determined as indexed from the date of the firs positive primary tumor as determined through histological examination. Individuals were righ censored based on last known histological follow-up <sup>60</sup> .	159	Patient and slide-level characteristics from the retrospective cohort are provided in Table 1. All
<ul> <li>161 criteria (negative, atypical, suspicious, positive). Separately, patient characteristics, e.g.,</li> <li>162 hematuria, prior treatments (e.g., BCG– Bacillus Calmette-Guerin or mitomycin) were record</li> <li>163 in a secure database <sup>59</sup>. Time to recurrence was determined as indexed from the date of the first</li> <li>164 positive primary tumor as determined through histological examination. Individuals were right</li> <li>165 censored based on last known histological follow-up <sup>60</sup>.</li> </ul>	160	slides were evaluated by five cytopathologists to provide diagnoses based on The Paris System
<ul> <li>hematuria, prior treatments (e.g., BCG– Bacillus Calmette-Guerin or mitomycin) were record</li> <li>in a secure database <sup>59</sup>. Time to recurrence was determined as indexed from the date of the firm</li> <li>positive primary tumor as determined through histological examination. Individuals were right</li> <li>censored based on last known histological follow-up <sup>60</sup>.</li> </ul>	161	criteria (negative, atypical, suspicious, positive). Separately, patient characteristics, e.g.,
<ul> <li>in a secure database <sup>59</sup>. Time to recurrence was determined as indexed from the date of the first</li> <li>positive primary tumor as determined through histological examination. Individuals were right</li> <li>censored based on last known histological follow-up <sup>60</sup>.</li> </ul>	162	hematuria, prior treatments (e.g., BCG- Bacillus Calmette-Guerin or mitomycin) were recorded
<ul> <li>positive primary tumor as determined through histological examination. Individuals were righ</li> <li>censored based on last known histological follow-up <sup>60</sup>.</li> </ul>	163	in a secure database <sup>59</sup> . Time to recurrence was determined as indexed from the date of the first
165 censored based on last known histological follow-up $^{60}$ .	164	positive primary tumor as determined through histological examination. Individuals were right
	165	censored based on last known histological follow-up 60.

	Specimens		Patients
Number	1259	Number Patients	135
Specimens			
Voided (%)	1110 (88.2)	Age (mean (SD))	71.50
			(12.26)
Prior	172 (13.7)	Sex = M(%)	102 (75.6)
History			
Hematuria			
(%)			
Diagnosis		First Positive Primary Tumor Stage	/Grade (%)
(%)			
Negative	815 (64.7)	Ois	7 (5.2)
Atypical	298 (23.7)	T1	35 (25.9)
Suspicious	98 (7.8)	TaLG (non-invasive low grade)	33 (24.4)
Positive	48 (3.8)	TaHG (non-invasive high grade)	60 (44.4)
Contains	265 (21.0)	Carcinoma in situ (%)	18 (13.3)
Artifact			
(%)			
		Treatment (%)	
		BCG	71 (52.6)
		Mitomycin	9 (6.7)
		No Treatment	37 (27.4)
		Unavailable	18(13.3)
		Number of Recurrences (%)	
		0	42 (31.1)

167 **Table 1:** Patient and specimen characteristics

	1	73 (54.1)
-	2	13 (9.6)
	3+	7 (5.2)

168

## 169 Using AutoParis-X to Derive Imaging Predictors of Recurrence

- 170 AutoParis-X is a tool for automated assessment of cytology specimens that was developed using
- 171 the Python programming language and the PyTorch and Detectron2 frameworks, with statistical
- and machine learning models implemented in Python and R<sup>40,61–64</sup>. In brief, this tool:
- 173 1. Utilizes connected components analysis to isolate individual cells and cell clusters
- 174 2. A neural network-based cell border detection model called BorderDet isolates urothelial
- 175 cells within clusters and identifies dense overlapping cell architectures <sup>65</sup>.
- Additional morphometric measures are derived for cell-type classification and atypia
   estimation <sup>34,40</sup>.

# A convolutional neural network called UroNet filters out any objects which are not urothelial cells <sup>34,40</sup>.

- 180 5. A segmentation neural network method called UroSeg estimates the nuclear-to-cytoplasm
   181 ratio <sup>34,40</sup>.
- A convolutional neural network called AtyNet scores cells for subjective markers of
   atypia <sup>40</sup>.

A machine learning classifier estimates the Atypia Burden Score (ABS) which integrates
 cell and cluster-level scores and other demographic and specimen characteristics into a
 summary measure of overall specimen atypia <sup>66–68</sup>.

In addition, hierarchical regression models identified important indicators of atypia, and
 graphical displays were generated through an interactive web application utilized by our
 team of cytopathologists <sup>69,70</sup>.

190 A description of slide level measures and ABS scores, listed in Supplementary Table 1, which 191 were derived for each specimen in this cohort.

192

#### 193 **Recurrence Prediction**

194 Time to recurrence was predicted using both traditional cytological measures and AutoParis-X

195 derived imaging features (Figure 1B), controlling for age and sex, prior treatment, tumor grade,

196 medical history, etc., where possible- e.g., treatment information was largely excluded from

197 multivariable modeling due to missingness and uncertainty in treatment time.

198

199 Fixed recurrence predictors. First, we aggregated imaging/cytology statistics (e.g., average 200 number of atypical cells) for cytology exams before/at the primary diagnosis date or within a 201 specific time frame after the primary diagnosis date (i.e., *collection time*) (Figure 1C). It is 202 important to ensure that data is collected up to a specific date in order to accurately assess risk 203 for new patients. This is because collecting data beyond this point would introduce information 204 about the future and potentially bias the results. To ensure that the findings remain applicable, 205 data for new patients must be collected only up to the defined collection time. Cases were 206 excluded if events/censoring occurred before this collection window and recurrence times were 207 adjusted as appropriate (i.e., delayed entry) to avoid endogeneity. We denote predictors during 208 this time period as *fixed predictors*. Fixed predictors were modeled using multivariable cox 209 proportional hazards models <sup>71</sup>:

 $days\_to\_event_i | censored_i = 0 \sim Exponential(\lambda_i)$  $days\_to\_event_i | censored_i = 0 \sim Exponential - CCDF(\lambda_i)$ 210 211

211 
$$aays_{i}c_{event_{i}}censorea_{i} = 0 \sim Exponential = 0$$
  
212  $f(y) = \lambda_{i}e^{-\lambda_{i}y}$ 

- $\lambda_i = 1/\mu_i \\ \log(\mu_i) = x_i^T \beta$ 214
- 215

216 The predictive performance of leveraging fixed (i.e., collected) UC imaging predictors was 217 compared to the histological examination, e.g., tumor grade/stage and whether the tumor was 218 carcinoma in situ (Cis). Separate cox models were fit to the imaging predictors alone, tumor 219 grade and carcinoma in situ, and both, adjusting for age and sex. Models were compared through 220 partial likelihood ratio testing, which would indicate whether imaging predictors alone were 221 more informative than the histological findings (H1: Imaging>Grade+Cis) and separately 222 whether the imaging predictors supplemented tumor grade information to add additional 223 predictive capacity (H<sub>1</sub>: Imaging+Grade+Cis>Grade+Cis). We separately reported the hazard 224 ratios for the imaging predictors after adjusting for tumor grade/stage and Cis. Results were 225 compared at all collection times. We did not adjust models for whether the patients had 226 chemotherapy due to unreliability in recording patient start date and adherence, though this 227 information was recorded in the demographic tables for additional context.

228

Dynamic recurrence predictors. Time-dependent predictors (denoted as dynamic predictors)
were modeled using cox proportional hazards models which allowed repeat measures by patient.
These predictors were modeled with and without time varying effects (similar to estimating
multiple survival curves across discrete time intervals) (Figure 1D), which reports changes to the
relationship between predictors and recurrence as a function of time (i.e., certain intervals may
be more predictive of recurrence) <sup>53</sup>.

235

Individual predictors were modeled in a univariable setting, adjusting only for age and gender.
These variables were combined into multivariable models. Predictor selection was accomplished
using the variance inflation factor (VIF) after fitting the survival models and iteratively removing

239	predictors until the largest VIF score was less than 6.5 <sup>72</sup> . We had also performed LASSO
240	predictor selection but opted for VIF as these models outperformed LASSO <sup>73</sup> . Concordance
241	statistics (C-index; as reported using the survival R package) were reported for the univariable
242	and multivariable models, along with hazards ratios, confidence intervals and p-values. For the
243	time-varying effects, hazards ratios and their statistical significance were reported across time for
244	individual predictors and overall across many predictors <sup>54</sup> . Hazard predictions were
245	dichotomized into low and high risk and <i>fixed predictors</i> were visualized using Kaplan Meier
246	plots using the survminer package (R v4.1) <sup>74</sup> .

247

#### 248 Studying Trajectories of ABS Scores

249 After fitting the cox models, we additionally sought to uncover longitudinal patterns of atypia 250 related to high recurrence risk (Figure 1E). This was accomplished by clustering the trajectories 251 of ABS scores across time using dynamic time warping (DTW). DTW was used to construct a 252 distance matrix between individual patient trajectories, which were reduced into two features per 253 patient using multi-dimensional scaling using the *scikit-time* library (Python v3.8) and *reticulate* 254 package (R v4.1) <sup>75,76</sup>. Separately, the patients were clustered using hierarchical clustering of the 255 DTW distance matrix via the *hclust* function (R v4.1). Cases were omitted if they did not contain 256 at least two points. Associations between the DTW clusters and features were identified through 257 generalized linear mixed effects modeling. The average ABS score was visualized across time, 258 aggregated for low-risk / high-risk patients and separately for the derived clusters at binned time 259 periods. Beta hierarchical regression models with post-hoc comparison via emmeans were used 260 to report how ABS differed between high and low risk patients across time <sup>55,56,77</sup>:

261  
262  
263  

$$ABS_i \sim \text{Beta}(\mu_i * \phi_i, (1 - \mu_i) * \phi_i)$$
263  

$$g(\mu_i) = \beta_0 + \beta_1 time_i + \beta_2 risk_i + \beta_3 time_i * risk_i + \theta_{patient[i]}; g(\cdot) : (0,1) \to \mathbb{R}$$

$$\theta_{patient[i]} \sim N(0, \tau^2)$$

We identified several patients who had multiple recurrences. We visualized changes in ABS 264

265 before and after recurrences by creating scatter plots of ABS versus time. We fit a hierarchical

266 beta regression model to depict overall changes in ABS score across time between patients' first

267 and second recurrences, with similar hierarchical beta regression models fit, excluding risk from

268 the model.

269

270 **Results** 

#### 271 **Recurrence Predicted from Fixed Predictors**

272 Fitting cox proportional hazards models at various collection times, we found there was

273 moderate ability to predict recurrence using UC imaging predictors (Figure 2C,D;

274 Supplementary Figure 1; Supplementary Table 2). When only collecting cytological

275 information up to the first positive primary (collection time = 0 days), imaging and manually

276 assessed UC class predictors yielded a C-index of 0.672. Overall, imaging predictors were more

277 informative than manual cytological examination (Supplementary Table 2, see "% Outperform

278 UC Class", number of imaging predictor with better performance than manual examination). The

279 predictiveness of the UC imaging predictors increased when predictors were aggregated across

280 larger time intervals / collection times, for instance yielding a C-index of 0.77 when collecting

- 281 quantitative cytological information over the first 180 days after the first positive primary
- 282 (collection time = 180 days). Collecting cytological information past this point in time and
- 283 aggregating yielded marginal to no additional information on recurrence. The imaging variables

284 differed significantly in their predictive capacity. Surprisingly, imaging features extracted from

- 285 urothelial cell clusters proved remarkably predictive (C-index for: number of atypical cell
- clusters = 0.733; number of dense cell clusters = 0.748 at collection time 180 days) as opposed to
- variables which correlate more closely with UC Class (e.g., ABS).
- 288
- 289 Imaging predictors extracted from cytology and separately in conjunction with risk assessment
- 290 models based on tumor grade/type were more informative for recurrence risk prediction than that
- derived from tumor grade/type alone (Supplementary Figure 2; Supplementary Table 3), as
- assessed through partial likelihood ratio testing <sup>78,79</sup>. At nearly every collection interval, imaging
- 293 predictors demonstrated statistically significantly better predictive capacity than tumor
- 294 grade/type alone and effects from the imaging predictors were highly statistically significant,

even after adjusting for tumor grade/type (**Supplementary Table 3**).



298 Figure 2: Findings from Recurrence Risk Models: A) Dot chart indicating concordance 299 statistics for each of the imaging predictors for the *time-varying covariate* and *time-varying* 300 *effects* cox proportional hazards models; UC class stands for category assigned via manual 301 examination by the cytopathologist; VIF and LASSO refer to multivariable models with the 302 respective predictor selection methods; All/Overall predictors refers to multivariable models with 303 all imaging predictors; B) Ribbon plot illustrating hazard ratios and confidence intervals for 304 univariable *time-varying effects* cox proportional hazards model for individual imaging 305 predictors, demonstrating differing associations with recurrence at distinct time intervals; C) 306 Kaplan-Meier plot and rank-based statistic for *fixed imaging predictors* collected before or up to 307 the date of the first positive primary, reported for low (blue) and high (yellow) risk patients as 308 assessed using the Cox model; **D**) similar KM plot for patients with 90 days of follow-up 309 information collected, predicting recurrence risk after this collection period

310

## 311 Recurrence Predicted from Dynamic Predictors

312 When considering all individual cytology exams dynamically over time (*time-varying* 

313 covariates) and not aggregating across distinct time windows, imaging predictors corresponded

314 with recurrence with a C-index of 0.66 (Figure 2A; Supplementary Table 2). The Atypical

315 Score (C-index=0.65) was more predictive than UC Class (C-index=0.58) using this approach.

316 Fitting recurrence models, allowing effects of different predictors to vary- these time varying

317 effects were reported for each distinct time period (*time-varying effects*; association between

318 variables and recurrence risk updated every half year; Figure 2B), achieved an overall C-index

319 of 0.73, greater than that offered by the *time-varying covariates*. The Atypical Score (C-

320 index=0.65) was still more predictive than UC Class (C-index=0.62) using this approach

321 (Supplementary Table 4). The association between individual imaging predictors and

322 recurrence risk varied across these intervals (Figure 2B; Supplementary Table 5). For instance,

323 ABS and UC Class were highly positively associated with recurrence risk during the first year

and after the second year of follow-up (Figure 2B; Supplementary Table 5). As another

325 example, the number of atypical cells and atypical clusters demonstrated their greatest

- 326 association with recurrence risk at intermediate intervals (e.g., 180-540 days) (Figure 2B;
- 327 Supplementary Table 5).
- 328
- 329 Trajectory Cluster Analysis



![](_page_14_Figure_6.jpeg)

## **Figure 3: Atypia Burden Scores reported across time, aggregated across distinct time**

periods using point interval plots: A) Each curve/color represents ABS scores from patients
 belonging to three different temporal trajectories (red, blue, green clusters), determined using the

334 time series clustering and summarized using the aggregate statistics for each time period; **B**)

Each curve is colored based on low (blue) and high (yellow) risk patients, measured from the

336 time since first positive primary; C) Comparing ABS scores between low/high risk patients,

- 337 similar to the previous plot, with cytological exams grouped by days until the first recurrence
- instead of from the date of the first positive primary; **D**) ABS scores, combined across distinct
- time periods, for patients from the first until the second recurrence, grouped by the days until the
- 340 second recurrence, demonstrating increasing atypia prior to the recurrence finding
- 341
- 342 We sought to study the trajectories of specimen atypia from the first positive primary to the first
- 343 recurrence. Time series clustering yielded three independent clusters (Figure 3A). The red

cluster (Figure 3A) revealed the tendency of patients to exhibit a decrease in specimen atypia
immediately after the positive primary (likely resulting from previous treatment), followed by a
sharp increase in specimen atypia thereafter. Patients deemed high risk by the Cox models
(Figure 3B,C) initially have a low atypical burden, similar to the low risk group. However, over
time after the positive primary, the discrepancies in specimen atypia increase substantially
(Figure 3B; Supplementary Table 6). When counting down backwards from the date of first

recurrence, we see that specimen atypia increases steadily from both low and high risk patients
prior to the first recurrence. Within 3-4 months prior to the first recurrence, specimen atypia for

352 the low-risk patients decreases while continuing to increase for the high risk patients (Figure

**353 3C; Supplementary Table 6**).

354

These trends were similarly identified for patients who had a first recurrence who would go onto have a second recurrence (**Figure 3D**; **Supplementary Table 6**; **Supplementary Figure 3**). A statistically significant increase in overall specimen atypia over time was identified during this interval between the first and second recurrences (**Supplementary Table 6**). The Atypia Burden Scores plotted across time from positive primary date for patients with multiple recurrences can be found in **Supplementary Figure 4**, though an in-depth assessment is outside of the scope of this study.

362

#### 363 Discussion

Bladder cancer has a high rate of recurrence, which requires frequent follow up screening and
monitoring. By using advanced computer algorithms, it is possible to create a non-invasive,
semi-autonomous system that can analyze repeat cytology exams and provide highly precise

367 markers of specimen atypia <sup>34,36,40</sup>. This approach can improve our understanding of how bladder 368 cancer progresses and recurs, as well as identify patterns that indicate early detection of 369 recurrence. This study sought to investigate the potential utility of such an approach, made 370 possible by the AutoParis-X tool, which can facilitate rapid examination of cytology specimens 371 <sup>40</sup>. Imaging predictors derived using AutoParis-X such as the Atypia Burden Score and other 372 sub-scores (e.g., number of atypical clusters) were followed across time for patients and were 373 aggregated across distinct time periods and studied *dynamically* to predict bladder cancer 374 recurrence.

375

376 The principal findings from our study are twofold: 1) urine cytology exam results can inform 377 recurrence risk, and imaging predictors extracted through the use of machine learning can be 378 more informative of recurrence than manual cytological and/or histological examination alone; 379 and 2) the predictive value of imaging predictors extracted from UC exams varies across time 380 (both in terms of combining information from previous exams and real-time predictiveness of 381 time-variant predictors). Our findings support and add to previous studies showing that 382 preoperative urine cytology examination can predict recurrence <sup>80–82</sup>. We also found that 383 collecting and combining cytological information with summary statistics within the first six 384 months after the positive primary diagnosis is important for assessing recurrence risk for patients 385 who have not yet recurred. While there are several other machine learning techniques which 386 have been developed to perform histological assessments of recurrence risk from the primary site 387 at the time of resection, cytological assessments are far less invasive (requiring the patient to simply void into a collection cup in most cases) <sup>41,83</sup>. Due to routine screening via UC, more 388 389 information is available, which when assessed in totality, can be highly predictive of recurrence.

It is important to consider how information from cytological and histological examinations can be used together to provide more comprehensive assessment of risk. The use of imaging predictors extracted from cytology, both alone and in combination with tumor grade/type, provided more useful information for predicting recurrence risk compared to relying on tumor grade/type alone, as determined through partial likelihood ratio testing. The combination of cytological and histological assessments is especially pertinent for patients who have undergone a tumor resection and are identified to be at high risk from both cytology and histology.

398 There are limitations to this study. For instance, there is still ample room to improve the AutoParis-X algorithm, which can impact the reliability of these predictors <sup>40</sup>. Furthermore, we 399 400 have not studied its utility in augmenting medical diagnostic decision-making in conjunction 401 with the cytopathologist <sup>84–88</sup>. Changes in specimen preparation across the past decade and a half 402 may have impacted imaging predictors estimated using AutoParis-X. We used the last 403 histological follow up exam with a negative finding as a right censoring event for patients in this 404 cohort who did not ultimately develop recurrence <sup>89</sup>. As this was a retrospective cohort study 405 with sporadic follow-up (typically every three months as specified by guidelines), it was 406 challenging to identify suitable follow-up and censorship criteria. Furthermore, death may 407 present a competing risk to recurrence, which could potentially bias effect estimates. While 408 methods do exist to account for competing risks, relevant statistical methods and their 409 computational implementations are underdeveloped and inaccessible in the context of timevarying covariates and effects<sup>90,91</sup>. These limitations will be improved upon in further 410 411 assessments of this tool and these study findings should be interpreted in the context of an 412 exploratory analysis. The study cohort was restricted to individuals from Northern New England

and findings are applicable to this population– expansion of this study to large, diverse study
cohorts from geographically disparate regions will improve the generalizability of these findings.

In the future, we plan to leverage additional machine learning techniques which are suitable for recurrence prediction. For instance, tree-boosting approaches and deep learning models exist which are well-suited for the study of longitudinal / time-to-event data <sup>92–105</sup>. They can reveal interactions between predictors for use in statistical modeling as well as identify cytology exams / timepoints which are most informative of recurrence <sup>106</sup>. These are estimated dynamically using sophisticated computational heuristics and are an area of future follow-up.

422

423 The results of this study highlight the need for further research comparing the performance of the 424 AutoParis-X system with other non-invasive methods for assessing the potential for bladder 425 cancer recurrence. Many promising approaches make use of various molecular assays developed 426 for liquid biopsies, and several screening programs have also been developed that use a 427 combination of different assays to assess the potential for recurrence <sup>107–114</sup>. These should be 428 considered for comparison when attempting to roll out potential screening systems/guidelines. 429 While early detection of recurrence is important, it is currently unclear what the next steps 430 should be in terms of treatment and management given the adoption of computational systems for real-time recurrence assessment <sup>35,39,115–117</sup>. This is an area that requires further research. 431 432 Furthermore, there are a wide-range of epidemiological studies which could benefit from 433 incorporating cytological information. For instance, exposure to high levels of arsenic in 434 drinking water and cigarette smoking are associated with bladder cancer risk and could benefit

from being studied in conjunction with advanced computational methods for urine cytology <sup>118–</sup>
<sup>123</sup>.

437

#### 438 Conclusion

439 This study sought to investigate the potential benefit of using computer algorithms to extract

440 highly quantitative, longitudinal cytological features can be used to inform the risk of recurrence

441 for bladder cancer patients. We found that image predictors extracted using the AutoParis-X

442 system were indeed associated with tumor recurrence, in many cases more so than traditional

443 modes of cytological/histological examination, and that the importance/predictiveness of these

444 predictors varied across time from the positive primary. While this study demonstrates the

445 potential utility for computerized systems to supplement and make use of screening programs

446 with a large number of follow up visits, further research is warranted to better understand how

447 these systems can be integrated into such screening programs.

## 449 **References**

- Kaufman, D. S., Shipley, W. U. & Feldman, A. S. Bladder cancer. *The Lancet* 374, 239–249 (2009).
- 453 2. Sanli, O. et al. Bladder cancer. Nature reviews Disease primers 3, 1–19 (2017).
- 454 3. Shalata, A. T. *et al.* Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer:
  455 Current Techniques and Future Trends. *Cancers* 14, 5019 (2022).
- 456 4. van der Meijden, A. *et al.* Significance of bladder biopsies in Ta, T1 bladder tumors:
  457 a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
  458 *European urology* 35, 267–271 (1999).
- Lokeshwar, V. B. & Soloway, M. S. Current bladder tumor tests: does their
  projected utility fulfill clinical necessity? *The Journal of urology* 165, 1067–1077
  (2001).
- 462 6. Griffiths, T. L. & Cancer, A. on B. Current perspectives in bladder cancer 463 management. *International journal of clinical practice* **67**, 435–448 (2013).
- 464 7. DeGeorge, K. C., Holt, H. R. & Hodges, S. C. Bladder cancer: diagnosis and
  465 treatment. *American family physician* 96, 507–514 (2017).
- 466 8. AJCC Cancer Staging Manual. (Springer International Publishing, 2017).
- 467 9. Rabbani, F., Perrotti, M., Russo, P. & Herr, H. W. Upper-tract tumors after an initial
  468 diagnosis of bladder cancer: argument for long-term surveillance. *J Clin Oncol* 19,
  469 94–100 (2001).
- 470 10. Zang, Y., Li, X., Cheng, Y., Qi, F. & Yang, N. An overview of patients with
  471 urothelial bladder cancer over the past two decades: a Surveillance, Epidemiology,
  472 and End Results (SEER) study. *Ann Transl Med* 8, 1587 (2020).
- 473 11. Schroeck, F. R. *et al.* Determinants of Risk-Aligned Bladder Cancer Surveillance—
  474 Mixed-Methods Evaluation Using the Tailored Implementation for Chronic
  475 Diseases Framework. *JCO Oncology Practice* 18, e152–e162 (2022).
- 476 12. van Rhijn, B. W. G. *et al.* Recurrence and Progression of Disease in Non–Muscle477 Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. *European*478 Urology 56, 430–442 (2009).
- 479 13. Mossanen, M. & Gore, J. L. The burden of bladder cancer care: direct and indirect
  480 costs. *Curr Opin Urol* 24, 487–491 (2014).
- 481 14. Bostwick, D. G. 7 Urine Cytology. in *Urologic Surgical Pathology (Fourth Edition)*482 (eds. Cheng, L., MacLennan, G. T. & Bostwick, D. G.) 322-357.e7 (Elsevier, 2020).
- 483 15. Stenzl, A., Hennenlotter, J. & Schilling, D. Can we still afford bladder cancer?
  484 *Current Opinion in Urology* 18, 488 (2008).
- Bruins, H. M. *et al.* The Importance of Hospital and Surgeon Volume as Major
  Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder
  Cancer: A Systematic Review and Recommendations by the European Association
  of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. *European Urology Oncology* 3, 131–144 (2020).
- Parekattil, S. J., Fisher, H. A. & Kogan, B. A. Neural network using combined urine
  nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary
  intercellular adhesion molecule-1 to detect bladder cancer. *The Journal of urology*169, 917–920 (2003).
- Halling, K. C. *et al.* A comparison of BTA stat, hemoglobin dipstick, telomerase and
  Vysis UroVysion assays for the detection of urothelial carcinoma in urine. *The Journal of urology* 167, 2001–2006 (2002).

- 497 19. Todenhöfer, T. *et al.* Stepwise application of urine markers to detect tumor
  498 recurrence in patients undergoing surveillance for non-muscle-invasive bladder
  499 cancer. *Disease markers* 2014, (2014).
- 500 20. Hendricksen, K. *et al.* Discrepancy Between European Association of Urology
  501 Guidelines and Daily Practice in the Management of Non–muscle-invasive Bladder
  502 Cancer: Results of a European Survey. *European Urology Focus* 5, 681–688 (2019).
- Raab, S. S., Grzybicki, D. M., Vrbin, C. M. & Geisinger, K. R. Urine cytology
  discrepancies: frequency, causes, and outcomes. *Am J Clin Pathol* 127, 946–953
  (2007).
- Zuiverloon, T. C. M., de Jong, F. C. & Theodorescu, D. Clinical Decision Making in
  Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of
  Urinary Cytology and Molecular Markers. *Oncology (Williston Park)* 31, 855–862
  (2017).
- Lin, D. W., Herr, H. W. & Dalbagni, G. Value of urethral wash cytology in the
  retained male urethra after radical cystoprostatectomy. *J Urol* 169, 961–963 (2003).
- 512 24. Levy, J. J. *et al.* Large-scale longitudinal comparison of urine cytological
  513 classification systems reveals potential early adoption of The Paris System criteria.
  514 *J Am Soc Cytopathol* S2213-2945(22)00241–1 (2022) doi:10.1016/j.jasc.2022.08.001.
- 515 25. Celik, B. & Kavas, G. Atypical category of the Johns Hopkins Template has higher
  516 ROM than the Paris System but the Paris system is more applicable for suspicious
  517 category. *Acta Cytol* (2023) doi:10.1159/000529484.
- 518 26. Morency, E. & Antic, T. Atypical urine cytology and the Johns Hopkins Hospital
  519 template: the University of Chicago experience. *J Am Soc Cytopathol* 3, 295–302
  520 (2014).
- 521 27. Rai, S. *et al.* A Quest for Accuracy: Evaluation of The Paris System in Diagnosis of
  522 Urothelial Carcinomas. *J Cytol* 36, 169–173 (2019).
- 523 28. Tian, W., Shore, K. T. & Shah, R. B. Significant reduction of indeterminate (atypical)
  524 diagnosis after implementation of The Paris System for Reporting Urinary
  525 Cytology: A single-institution study of more than 27,000 cases. *Cancer Cytopathology*526 **129**, 114–120 (2021).
- 527 29. Barkan, G. A. *et al.* The Paris System for Reporting Urinary Cytology: The Quest to
  528 Develop a Standardized Terminology. *ACY* 60, 185–197 (2016).
- 529 30. Wojcik, E. M., Kurtycz, D. F. & Rosenthal, D. L. *The Paris system for reporting urinary* 530 *cytology*. (Springer, 2022).
- 531 31. Kurtycz, D. F. *et al.* Paris interobserver reproducibility study (PIRST). *Journal of the* 532 *American Society of Cytopathology* 7, 174–184 (2018).
- 533 32. Long, T. *et al.* Interobserver reproducibility of The Paris System for Reporting
  534 Urinary Cytology. *Cytojournal* 14, 17 (2017).
- 535 33. Lebret, T. *et al.* VISIOCYT1 clinical trial: Artificial intelligence for the diagnosis of 536 bladder urothelial lesions. *JCO* **40**, e16558–e16558 (2022).
- 537 34. Vaickus, L. J., Suriawinata, A. A., Wei, J. W. & Liu, X. Automating the Paris System
  538 for urine cytopathology—A hybrid deep-learning and morphometric approach.
  539 *Cancer Cytopathology* 127, 98–115 (2019).
- 540 35. McAlpine, E. D., Pantanowitz, L. & Michelow, P. M. Challenges Developing Deep
  541 Learning Algorithms in Cytology. ACY 65, 301–309 (2021).
- Sanghvi, A. B., Allen, E. Z., Callenberg, K. M. & Pantanowitz, L. Performance of an
  artificial intelligence algorithm for reporting urine cytopathology. *Cancer Cytopathology* 127, 658–666 (2019).

- 545 37. Awan, R. *et al.* Deep learning based digital cell profiles for risk stratification of
  546 urine cytology images. *Cytometry Part A* 99, 732–742 (2021).
- 54738. Kaneko, M. *et al.* Urine cell image recognition using a deep-learning model for an<br/>automated slide evaluation system. *BJU Int* (2021) doi:10.1111/bju.15518.
- Substrain Strain Stra
- 40. Levy, J. *et al.* Large-Scale Validation Study of an Improved Semi-Autonomous
  Urine Cytology Assessment Tool: AutoParis-X. 2023.03.01.23286639 Preprint at
  https://doi.org/10.1101/2023.03.01.23286639 (2023).
- 555 41. Barrios, W. *et al.* Bladder cancer prognosis using deep neural networks and 556 histopathology images. *Journal of Pathology Informatics* **13**, 100135 (2022).
- Lucas, M. *et al.* Deep Learning–based Recurrence Prediction in Patients with Non–
   muscle-invasive Bladder Cancer. *European Urology Focus* 8, 165–172 (2022).
- 43. Karakiewicz, P. I. *et al.* Institutional variability in the accuracy of urinary cytology
  for predicting recurrence of transitional cell carcinoma of the bladder. *BJU Int* 97,
  997–1001 (2006).
- 44. Lotan, Y. *et al.* Clinical comparison of noninvasive urine tests for ruling out
  recurrent urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations* 35, 531.e15-531.e22 (2017).
- 565 45. Schroeck, F. R. *et al.* Data-driven approach to implementation mapping for the
  566 selection of implementation strategies: a case example for risk-aligned bladder
  567 cancer surveillance. *Implementation Sci* 17, 58 (2022).
- 568 46. Sullivan, P. S., Chan, J. B., Levin, M. R. & Rao, J. Urine cytology and adjunct
  569 markers for detection and surveillance of bladder cancer. *Am J Transl Res* 2, 412–440
  570 (2010).
- 571 47. Nabi, G., Greene, D. R. & O'Donnell, M. How Important is Urinary Cytology in the
  572 Diagnosis of Urological Malignancies? *European Urology* 43, 632–636 (2003).
- 48. Kent, D. L., Nease, R. A., Sox, H. C., Shortliffe, L. D. & Shachter, R. Eualuation of
  Nonlinear Optimization for Scheduling of follow-up cystoscopies to Detect
  Recurrent Bladder Cancer. *Med Decis Making* 11, 240–248 (1991).
- 576 49. Schrag, D. *et al.* Adherence to Surveillance Among Patients With Superficial
  577 Bladder Cancer. *JNCI: Journal of the National Cancer Institute* **95**, 588–597 (2003).
- 578 50. van, der A. M. N. M. *et al.* Cystoscopy Revisited as the Gold Standard for
  579 Detecting Bladder Cancer Recurrence: Diagnostic Review Bias in the Randomized,
  580 Prospective CEFUB Trial. *Journal of Urology* 183, 76–80 (2010).
- 581 51. Schober, P. & Vetter, T. R. Survival Analysis and Interpretation of Time-to-Event 582 Data: The Tortoise and the Hare. *Anesth Analg* **127**, 792–798 (2018).
- 583 52. Lin, D. Y. & Wei, L. J. The Robust Inference for the Cox Proportional Hazards
  584 Model. *Journal of the American Statistical Association* 84, 1074–1078 (1989).
- 585 53. Fisher, L. D. & Lin, D. Y. Time-Dependent Covariates in the Cox Proportional-586 Hazards Regression Model. *Annual Review of Public Health* **20**, 145–157 (1999).
- 587 54. Scheike, T. H. Time-Varying Effects in Survival Analysis. in *Handbook of Statistics*588 vol. 23 61–85 (Elsevier, 2003).
- 589 55. Cribari-Neto, F. & Zeileis, A. Beta Regression in R. *Journal of Statistical Software* 34, 1–24 (2010).
- 591 56. Brooks, M. E. *et al.* glmmTMB balances speed and flexibility among packages for 592 Zero-inflated Generalized Linear Mixed Modeling. *R Journal* **9**, 378–400 (2017).

- 57. Okuda, C. *et al.* Quantitative cytomorphological comparison of SurePath and
  ThinPrep liquid-based cytology using high-grade urothelial carcinoma cells. *Cytopathology* 32, 654–659 (2021).
- 58. Kim, D. *et al.* Evaluating the role of Z-stack to improve the morphologic evaluation of urine cytology whole slide images for high-grade urothelial carcinoma: Results and review of a pilot study. *Cancer Cytopathology* **130**, 630–639 (2022).
- 59. B, Ö. A., Jocham, D. & Bock, P. R. Intravesical Bacillus Calmette-Guerin Versus
  Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of
  Comparative Studies on Recurrence and Toxicity. *Journal of Urology* 169, 90–95
  (2003).
- 603
  60. Chen, H. *et al.* Urine cytology in monitoring recurrence in urothelial carcinoma
  604
  605
  605
  605
  606
  607
  607
  608
  609
  609
  609
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600</
- 606 61. Tippmann, S. Programming tools: Adventures with R. *Nature* **517**, 109–110 (2015).
- 607 62. Matthes, E. Python Crash Course, 2nd Edition: A Hands-On, Project-Based Introduction
   608 to Programming. (No Starch Press, 2019).
- 609 63. Paszke, A. *et al.* PyTorch: An Imperative Style, High-Performance Deep Learning
  610 Library. *arXiv*:1912.01703 [cs, stat] (2019).
- 611 64. Wu, Y., Kirillov, A., Massa, F., Lo, W.-Y. & Girshick, R. Detectron2. (2019).
- 65. Levy, J. J. *et al.* Uncovering additional predictors of urothelial carcinoma from
  voided urothelial cell clusters through a deep learning-based image preprocessing
  technique. *Cancer Cytopathol* (2022) doi:10.1002/cncy.22633.
- 615 66. Sigrist, F. Latent Gaussian Model Boosting. *IEEE Transactions on Pattern Analysis* 616 *and Machine Intelligence* 1–1 (2022) doi:10.1109/TPAMI.2022.3168152.
- 617 67. Sigrist, F. Gaussian Process Boosting. *Journal of Machine Learning Research* **23**, 1–46 (2022).
- 619 68. Tan, Y. V. & Roy, J. Bayesian additive regression trees and the General BART
  620 model. *Statistics in Medicine* 38, 5048–5069 (2019).
- 621 69. Bürkner, P.-C. Advanced Bayesian Multilevel Modeling with the R Package brms.
  622 *The R Journal* 10, 395–411 (2018).
- 623 70. Modern Analytic Apps for the Enterprise. *Plotly* https://plot.ly.
- 624 71. Therneau, T. M., until 2009), T. L. (original S.->R port and R. maintainer, Elizabeth,
  625 A. & Cynthia, C. survival: Survival Analysis. (2023).
- Thompson, C. G., Kim, R. S., Aloe, A. M. & Becker, B. J. Extracting the variance
  inflation factor and other multicollinearity diagnostics from typical regression *Basic and Applied Social Psychology* 39, 81–90 (2017).
- 629 73. Ranstam, J. & Cook, J. A. LASSO regression. *British Journal of Surgery* 105, 1348
   630 (2018).
- 631 74. Kassambara, A., Kosinski, M., Biecek, P. & Fabian, S. survminer: Drawing Survival
  632 Curves using 'ggplot2'. (2021).
- 633 75. Löning, M. *et al.* sktime: A Unified Interface for Machine Learning with Time
  634 Series. Preprint at https://doi.org/10.48550/arXiv.1909.07872 (2019).
- 635 76. Kalinowski, T. *et al.* reticulate: Interface to 'Python'. (2023).
- 636 77. Lenth, R. V. *et al.* emmeans: Estimated Marginal Means, aka Least-Squares Means.637 (2023).
- Ravvaz, K., Weissert, J. A. & Downs, T. M. American Urological Association
  Nonmuscle Invasive Bladder Cancer Risk Model Validation—Should Patient Age
  be Added to the Risk Model? *The Journal of Urology* (2019)
- 641 doi:10.1097/JU.00000000000389.

- 642 79. Vuong, Q. H. Likelihood ratio tests for model selection and non-nested hypotheses.
   643 *Econometrica* 57, 307–333 (1989).
- 644 80. Chow, N.-H., Tzai, T.-S., Cheng, H.-L., Chan, S.-H. & Lin, J. S.-N. Urinary
  645 Cytodiagnosis: Can It Have a Different Prognostic Implication than a Diagnostic
  646 Test? *UIN* 53, 18–23 (1994).
- 647 81. Liu, W. *et al.* Preoperative positive voided urine cytology predicts poor clinical
  648 outcomes in patients with upper tract urothelial carcinoma undergoing
  649 nephroureterectomy. *BMC Cancer* 20, 1113 (2020).
- 82. Fan, B. *et al.* Predictive Value of Preoperative Positive Urine Cytology for
  Development of Bladder Cancer After Nephroureterectomy in Patients With Upper
  Urinary Tract Urothelial Carcinoma: A Prognostic Nomogram Based on a
  Retrospective Multicenter Cohort Study and Systematic Meta-Analysis. *Front Oncol*11, 731318 (2021).
- 83. Tokuyama, N. *et al.* Prediction of non-muscle invasive bladder cancer recurrence
  using machine learning of quantitative nuclear features. *Mod Pathol* 35, 533–538
  (2022).
- 84. Li, R. C., Asch, S. M. & Shah, N. H. Developing a delivery science for artificial
  intelligence in healthcare. *npj Digit. Med.* 3, 1–3 (2020).
- 85. Yildirim, N., Zimmerman, J. & Preum, S. Technical Feasibility, Financial Viability,
  and Clinician Acceptance: On the Many Challenges to AI in Clinical Practice. in
  HUMAN@ AAAI Fall Symposium (2021).
- 86. Salto-Tellez, M. More than a decade of molecular diagnostic cytopathology leading
  diagnostic and therapeutic decision-making. *Archives of pathology & laboratory medicine* 142, 443–445 (2018).
- 666 87. Cai, C. J., Winter, S., Steiner, D., Wilcox, L. & Terry, M. ' Hello AI': uncovering the
  667 onboarding needs of medical practitioners for human-AI collaborative decision668 making. *Proceedings of the ACM on Human-computer Interaction* 3, 1–24 (2019).
- 88. Van Es, S. L., Kumar, R. K., Pryor, W. M., Salisbury, E. L. & Velan, G. M.
  670 Cytopathology whole slide images and adaptive tutorials for senior medical
  671 students: a randomized crossover trial. *Diagnostic Pathology* **11**, 1–9 (2016).
- 89. Yoder, B. J. *et al.* Reflex UroVysion Testing of Bladder Cancer Surveillance Patients
  With Equivocal or Negative Urine Cytology: A Prospective Study With Focus on
  the Natural History of Anticipatory Positive Findings. *American Journal of Clinical Pathology* 127, 295–301 (2007).
- 676 90. Fine, J. P. & Gray, R. J. A Proportional Hazards Model for the Subdistribution of a
  677 Competing Risk. *Journal of the American Statistical Association* 94, 496–509 (1999).
- Austin, P. C., Putter, H., Lee, D. S. & Steyerberg, E. W. Estimation of the Absolute
  Risk of Cardiovascular Disease and Other Events: Issues With the Use of Multiple
  Fine-Gray Subdistribution Hazard Models. *Circulation: Cardiovascular Quality and Outcomes* 15, e008368 (2022).
- Barnwal, A., Cho, H. & Hocking, T. Survival Regression with Accelerated Failure
  Time Model in XGBoost. *Journal of Computational and Graphical Statistics* 31, 1292–
  1302 (2022).
- Sonabend, R., Király, F. J., Bender, A., Bischl, B. & Lang, M. mlr3proba: an R
  package for machine learning in survival analysis. *Bioinformatics* 37, 2789–2791
  (2021).
- Wang, Z. & Sun, J. Survtrace: Transformers for survival analysis with competing
  events. in *Proceedings of the 13th ACM International Conference on Bioinformatics, Computational Biology and Health Informatics* 1–9 (2022).

691 95. Kvamme, H., Borgan, Ø. & Scheel, I. Time-to-Event Prediction with Neural 692 Networks and Cox Regression. *Journal of Machine Learning Research* **20**, 1–30 (2019). 693 96. Pölsterl, S. scikit-survival: A Library for Time-to-Event Analysis Built on Top of 694 scikit-learn. The Journal of Machine Learning Research 21, 8747–8752 (2020). 695 97. Davidson-Pilon, C. lifelines: survival analysis in Python. Journal of Open Source 696 Software 4, 1317 (2019). 697 98. Tang, W., Ma, J., Mei, Q. & Zhu, J. SODEN: A Scalable Continuous-Time Survival 698 Model through Ordinary Differential Equation Networks. J. Mach. Learn. Res. 23, 699 34–1 (2022). 700 99. Nagpal, C., Potosnak, W. & Dubrawski, A. auton-survival: an Open-Source 701 Package for Regression, Counterfactual Estimation, Evaluation and Phenotyping 702 with Censored Time-to-Event Data. arXiv preprint arXiv:2204.07276 (2022). 703 100. Scheike, T. H. & Zhang, M.-J. Analyzing competing risk data using the R timereg 704 package. *Journal of statistical software* **38**, (2011). 705 101. Bender, A. & Scheipl, F. Pammtools: Piece-wise exponential additive mixed 706 modeling tools. *arXiv preprint arXiv:1806.01042* (2018). 707 102. Wang, P., Li, Y. & Reddy, C. K. Machine learning for survival analysis: A survey. 708 *ACM Computing Surveys (CSUR)* **51**, 1–36 (2019). 709 103. Alaa, A. M. & van der Schaar, M. Deep multi-task gaussian processes for survival 710 analysis with competing risks. in *Proceedings of the 31st International Conference on* 711 Neural Information Processing Systems 2326–2334 (2017). 104. Ranganath, R., Perotte, A., Elhadad, N. & Blei, D. Deep survival analysis. in 712 713 Machine Learning for Healthcare Conference 101–114 (PMLR, 2016). 714 105. Fernández, T., Rivera, N. & Teh, Y. W. Gaussian processes for survival analysis. 715 Advances in Neural Information Processing Systems **29**, (2016). 106. Levy, J. J. & O'Malley, A. J. Don't dismiss logistic regression: the case for sensible 716 717 extraction of interactions in the era of machine learning. BMC Med Res Methodol 20, 718 171 (2020). 719 107. Birkenkamp-Demtröder, K. et al. Monitoring treatment response and metastatic 720 relapse in advanced bladder cancer by liquid biopsy analysis. European urology 73, 721 535–540 (2018). 108. Crocetto, F. et al. Liquid biopsy in bladder cancer: State of the art and future 722 723 perspectives. Critical Reviews in Oncology/Hematology 103577 (2022). 724 109. Ferro, M. et al. Liquid biopsy biomarkers in urine: A route towards molecular 725 diagnosis and personalized medicine of bladder cancer. Journal of personalized 726 *medicine* **11**, 237 (2021). 727 110. Lodewijk, I. et al. Liquid biopsy biomarkers in bladder cancer: a current need for 728 patient diagnosis and monitoring. International journal of molecular sciences 19, 2514 729 (2018).730 111. Huang, H.-M. & Li, H.-X. Tumor heterogeneity and the potential role of liquid 731 biopsy in bladder cancer. *Cancer Communications* **41**, 91–108 (2021). 732 112. Oshi, M. *et al.* Urine as a source of liquid biopsy for cancer. *Cancers* **13**, 2652 (2021). 733 113. Todenhöfer, T., Struss, W. J., Seiler, R., Wyatt, A. W. & Black, P. C. Liquid biopsy-734 analysis of circulating tumor DNA (ctDNA) in bladder cancer. Bladder Cancer 4, 19– 735 29 (2018). 736 114. Wang, G. et al. Urine-based liquid biopsy in bladder cancer: Opportunities and 737 challenges. *Clinical and Translational Discovery* **3**, e176 (2023).

- 115. Tsuneki, M., Abe, M. & Kanavati, F. Deep Learning-Based Screening of Urothelial
  Carcinoma in Whole Slide Images of Liquid-Based Cytology Urine Specimens. *Cancers* 15, 226 (2023).
- 116. Nojima, S. *et al.* A deep learning system to diagnose the malignant potential of
  urothelial carcinoma cells in cytology specimens. *Cancer Cytopathology* 129, 984–995
  (2021).
- 117. McAlpine, E. D. & Michelow, P. The cytopathologist's role in developing and
  evaluating artificial intelligence in cytopathology practice. *Cytopathology* 31, 385–
  392 (2020).
- 118. Karagas, M. R. *et al.* Design of an epidemiologic study of drinking water arsenic
  exposure and skin and bladder cancer risk in a US population. *Environmental health perspectives* 106, 1047–1050 (1998).
- 119. Karagas, M. R., Stukel, T. A. & Tosteson, T. D. Assessment of cancer risk and
  environmental levels of arsenic in New Hampshire. *International journal of hygiene and environmental health* 205, 85–94 (2002).
- 120. Nuckols, J. R. *et al.* Estimating water supply arsenic levels in the New England
   Bladder Cancer Study. *Environmental health perspectives* 119, 1279–1285 (2011).
- 121. Koutros, S. *et al.* Potential effect modifiers of the arsenic–bladder cancer risk
   relationship. *International journal of cancer* 143, 2640–2646 (2018).
- 122. Baris, D. *et al.* Elevated bladder cancer in Northern New England: the role of
   drinking water and arsenic. *JNCI: Journal of the National Cancer Institute* 108, (2016).
- 123. Karagas, M. R. *et al.* Incidence of transitional cell carcinoma of the bladder and
   arsenic exposure in New Hampshire. *Cancer Causes & Control* 15, 465–472 (2004).

761

![](_page_27_Figure_1.jpeg)

Supplementary Figure 1: C-index for specific imaging / manual cytology exam results,

reported based on different collection periods/times (days) prior to the recurrence risk follow-up 768

769 period; only select AutoParis-X measurements of interest were reported

![](_page_28_Figure_1.jpeg)

Supplementary Figure 2: Comparison of KM plots for Imaging versus Histological Predictors, for cytological information collected across the following collection time periods after the first positive primary: A) 0 days, B) 90 days, C) 150 days, D) 210 days

![](_page_28_Figure_4.jpeg)

Time Until Second Recurrence (days)
 Supplementary Figure 3: Atypia Burden Score Versus Time Until Second Recurrence:
 Reported for 10 patients with at least 4 repeat exams across the period between their first and
 second recurrence

![](_page_29_Figure_1.jpeg)

![](_page_29_Figure_2.jpeg)

Supplementary Figure 4: Atypia Burden Score Versus Time Across Multiple Recurrence Events for Select Patients: Each recurrence date is represented with the vertical line

# Supplementary Table 1: Description of Slide Level predictors of Recurrence

Level	Predictor	Algorithm	Description
Cell	Urothelial cell	UroNet	Predicted probability of urothelial cell from convolutional neural network,
	score		used to dynamically isolate urothelial cells in specimen
	Atypia score	AtyNet	Predicted probability of presence of atypical features in urothelial cell (e.g.,
		-	hyperchromasia, irregular nuclear membrane, etc.), determined using
			convolutional neural network
	NC Ratio	UroSeg	Nuclear to cytoplasm area ratio derived from pixelwise segmentation of
		_	nucleus and cytoplasm using segmentatio neural network
	Morphometric	Custom	Complements binning of urothelial cells and assignment of atypia score,
	measures		features: 1) area; 2) convex area; 3) eccentricity; 4) equivalent diameter; 5)
			extent; 6) Feret's diameter; 7) maximum diameter; 8) filled area; 9) major axis
			length; 10) minor axis length; 11) perimeter; and 12) solidity
Cluste	Dense Area	BorderDet	Whether cluster contains dense architecture of overlapping and
r			indistinguishable cytoplasmic borders
	Number	BorderDet/	Whether cluster contained urothelial cells, determined by counting cells with
	urothelial cells	UroNet	high urothelial cell score
	Number	BorderDet/	Whether cluster contained abnormal urothelial cells, determined by counting
	atypical	UroNet/At	cells with high atypia score
	urothelial cells	yNet	
	(atypia score)		
	Number	BorderDet/	Whether cluster contained abnormal urothelial cells, determined by counting
	atypical	UroNet/Ur	cells with high NC ratio
	urothelial cells	oSeg	
	(NC ratio)		
	Dense &	BorderDet/	Whether cluster contained both dense architecture and atypical cellular
	Atypical	UroNet/At	features
		yNet/UroS	
		eg	

![](_page_29_Figure_7.jpeg)

Slide	Patient	Supplied	Includes age, sex, history of hematuria, specimen source (e.g., voided),
	characteristics		presence of specimen artifact
	Isolated Cell-	Bayesian	Counting the number of cells with the following features from cells not
	SIF Scores	Optimizati	associated with clusters: 1) cellularity (urothelial score), 2) atypia (atypia
		on	score), 3) atypia (NC ratio), 4) other morphometric measures
	Cluster Cell-	Bayesian	Counting the number of cells with the following features from cells
	SIF Scores	Optimizati	associated with clusters: 1) cellularity (urothelial score), 2) atypia (atypia
		score), 3) atypia (NC ratio), 4) other morphometric measures	
	All Cell-SIF	Bayesian	Combines Isolated Cell-SIF Scores and Cluster Cell-SIF Scores
	Scores	Optimizati	
		on	
	Cluster-SIF	Bayesian	Counting the number of clusters with the following features: 1) number of
		Optimizati	urothelial clusters, 2) atypical urothelial clusters (atypia score), 3) atypical
		on	clusters (NC ratio), 4) dense clusters, 5) dense and atypical clusters
	Atypia Burden	Mixed	Integrates all slide-level predictors using machine learning model to
	Score	effects	calculate a score between 0-1 reflecting overall specimen atypia, correlated
		machine	with UC diagnostic category
		learning	

788

789

## 790 Supplemental Table 2: Concordance statistics for *fixed predictors* at the following collection

time periods; also included are performance statistics for *dynamic predictors* from the *time-*

792 *varying covariate* cox model; the percentage of imaging variables which outperform manual

793 examination is represented as "% Outperform UC Class"

Collection Time 0		30		60		90		120		150		
(days)												
Predictors	С	SE	С	SE								
ABS	0.549	0.075	0.552	0.075	0.522	0.076	0.566	0.06	0.615	0.065	0.707	0.047
# Dense Clusters	0.62	0.069	0.62	0.069	0.6	0.069	0.581	0.061	0.666	0.066	0.74	0.051
UC Class	0.544	0.081	0.548	0.08	0.536	0.079	0.575	0.059	0.614	0.058	0.701	0.065
Eccentricity	0.558	0.084	0.564	0.088	0.515	0.078	0.557	0.059	0.662	0.059	0.716	0.048
# Isolated	0.56	0.077	0.56	0.077	0.524	0.077	0.562	0.059	0.615	0.064	0.704	0.042
Atypical Cells												
# Atypical	0.56	0.076	0.56	0.076	0.522	0.078	0.563	0.06	0.626	0.065	0.716	0.054
Clusters												
# Overall	0.562	0.079	0.56	0.077	0.524	0.076	0.565	0.059	0.623	0.063	0.701	0.047
Atypical Cells												
# Cluster	0.558	0.076	0.556	0.075	0.522	0.076	0.561	0.059	0.623	0.062	0.698	0.047
Atypical Cells												
% Clusters	0.554	0.076	0.554	0.076	0.519	0.077	0.564	0.06	0.631	0.051	0.683	0.054
Dense/Atypical												
# Isolated Cells	0.558	0.081	0.558	0.081	0.522	0.076	0.564	0.058	0.617	0.063	0.713	0.047
High NC												
# Overall Cells	0.56	0.08	0.56	0.08	0.526	0.077	0.566	0.059	0.616	0.063	0.713	0.047
High NC												
# Cluster Cells	0.562	0.077	0.562	0.077	0.522	0.08	0.562	0.059	0.62	0.062	0.71	0.046
High NC												
LASSO	0.59	0.084	0.603	0.073	0.578	0.069	0.584	0.06	0.654	0.058	0.74	0.051
# Cells	0.558	0.08	0.558	0.08	0.524	0.078	0.573	0.065	0.628	0.065	0.71	0.048
# Clusters	0.567	0.073	0.571	0.072	0.582	0.07	0.593	0.061	0.645	0.067	0.716	0.05
Overall	0.672	0.073	0.725	0.055	0.714	0.056	0.707	0.061	0.81	0.074	0.824	0.045
VIF	0.62	0.073	0.627	0.071	0.632	0.066	0.614	0.055	0.7	0.051	0.752	0.058
% Outperform												
UC Class	1.000	0.000	1.000	0.000	0.278	0.106	0.278	0.106	1.000	0.000	0.889	0.074
Collection Time	15	80	2	10	2.	10	2.	70	3(	00	Time V	arving
(days)		-		-		-				Cova	riates	
Predictors	С	SE	С	SE								
ABS	0.722	0.048	0.708	0.051	0.689	0.063	0.68	0.067	0.703	0.06	0.652	0.039
# Dense Clusters	0.748	0.05	0.688	0.058	0.727	0.057	0.725	0.055	0.727	0.066	0.603	0.038
UC Class	0.724	0.062	0.673	0.063	0.689	0.06	0.682	0.059	0.689	0.059	0.579	0.05
Eccentricity	0.724	0.048	0.697	0.059	0.665	0.073	0.639	0.076	0.699	0.068	0.607	0.034
•				-	-	-	-	-	-	-		

# Isolated	0.717	0.043	0.692	0.056	0.702	0.065	0.697	0.066	0.709	0.061	0.612	0.039
Atypical Cells												
# Atypical	0.733	0.053	0.716	0.062	0.7	0.067	0.702	0.064	0.712	0.06	0.62	0.039
Clusters												
# Overall	0.715	0.048	0.679	0.062	0.685	0.069	0.682	0.068	0.663	0.067	0.638	0.04
Atypical Cells												
# Cluster	0.713	0.048	0.681	0.064	0.685	0.069	0.68	0.069	0.651	0.068	0.637	0.042
Atypical Cells												
% Clusters	0.701	0.055	0.695	0.066	0.641	0.069	0.649	0.072	0.669	0.071	0.588	0.041
Dense/Atypical												
# Isolated Cells	0.724	0.046	0.664	0.061	0.709	0.066	0.69	0.066	0.689	0.063	0.588	0.039
High NC												
# Overall Cells	0.727	0.047	0.655	0.054	0.707	0.066	0.685	0.065	0.709	0.062	0.564	0.042
High NC												
# Cluster Cells	0.724	0.047	0.645	0.057	0.697	0.068	0.68	0.066	0.699	0.068	0.541	0.044
High NC												
LASSO	0.734	0.056	0.723	0.054	0.707	0.061	0.691	0.051	0.726	0.064	0.657	0.038
# Cells	0.724	0.045	0.705	0.052	0.707	0.058	0.692	0.063	0.712	0.059	0.631	0.039
# Clusters	0.727	0.049	0.702	0.053	0.743	0.051	0.719	0.056	0.677	0.067	0.6	0.039
Overall	0.827	0.046	0.849	0.051	0.927	0.035	0.92	0.036	0.911	0.03	0.659	0.041
VIF	0.773	0.058	0.747	0.057	0.731	0.061	0.743	0.074	0.746	0.06	0.682	0.036
% Outperform												
UC Class	0.611	0.115	0.722	0.106	0.667	0.111	0.611	0.115	0.667	0.111	0.778	0.098

795

## 796 Supplemental Table 3: Comparison between Cytological Imaging Predictors Versus

Histology: Hazard ratios, 95% confidence intervals and p-values, specifically after adjusting for
 tumor grade/type, reported for a variable constructed from the imaging predictors alone; also
 includes p-values from partial likelihood ratio test assessing whether imaging cytological exams

800 improves on histological predictors; reports for *fixed predictors* collected across various

801 collection time periods

Collection Time (days)	log(HR)	2.5% CI	97.5% CI	p-value	p-value– H1: Imaging> Grade+Cis	p-value– H1: Imaging+Grade+Cis> Grade+Cis
0	1.258	0.569	1.947	0.00035	0.220	0.048
30	1.199	0.533	1.865	0.00042	0.220	0.054
60	0.980	0.429	1.531	0.00049	0.060	0.042
90	0.982	0.319	1.646	0.00370	0.144	0.130
120	1.003	0.519	1.488	0.00005	0.115	0.102
150	1.019	0.538	1.499	0.00003	0.055	0.059
180	1.051	0.563	1.539	0.00002	0.060	0.060
210	1.081	0.542	1.621	0.00009	0.026	0.028
240	0.962	0.455	1.470	0.00020	0.024	0.017
270	0.974	0.517	1.432	0.00003	0.020	0.022
300	1.021	0.452	1.589	0.00044	0.016	0.017

802 803

#### 804 Supplementary Table 4: C-indices for Imaging Predictors from *Time-Varying Effects*

Models				
Predictor	С		SE	
ABS		0.65		0.039
Age		0.614		0.046
# Dense Clusters		0.578		0.037
UC Class		0.616		0.047
Eccentricity		0.563		0.049
Sex		0.54		0.041

# Isolated Atypical Cells	0.554	0.042
# Atypical Clusters	0.572	0.041
# Overall Atypical Cells	0.599	0.043
% Clusters	0.568	0.043
Dense/Atypical		
# Isolated Cells High NC	0.558	0.039
# Overall Cells High NC	0.557	0.04
# Cells	0.603	0.044
# Clusters	0.627	0.042
Overall	0.728	0.043

806

# 807 Supplementary Table 5: Hazard Ratios for Imaging Predictors from Time Varying Effects

808 **Models**; Predictor effect size and significance is reported for every half year, which was used as

809 the time periods to assess recurrence risk

Predictor	Time	log(HR)	2.5% CI	97.5% CI	Z	Pr(> z )
# Overall	0-180	1.39E-04	8.58E-05	1.93E-04	1.77E+00	7.63E-02
Atypical Cells	180-360	3.08E-04	1.90E-04	4.26E-04	1.51E+00	1.32E-01
	360-540	4.60E-04	3.12E-04	6.07E-04	1.50E+00	1.33E-01
	540-720	7.25E-04	1.53E-04	1.30E-03	6.43E-01	5.20E-01
	720-900	-6.14E-04	-1.84E-03	6.08E-04	-6.91E-01	4.89E-01
	>900	1.38E-03	8.03E-04	1.95E-03	1.10E+00	2.69E-01
# Overall Cells	0-180	2.03E-04	-2.87E-05	4.35E-04	6.93E-01	4.89E-01
High NC	180-360	8.75E-04	4.99E-04	1.25E-03	2.35E+00	1.89E-02
	360-540	1.52E-03	9.92E-04	2.05E-03	1.29E+00	1.98E-01
	540-720	1.09E-03	-1.20E-04	2.30E-03	5.60E-01	5.75E-01
	720-900	-5.97E-05	-2.13E-03	2.01E-03	-3.43E-02	9.73E-01
	>900	8.15E-03	6.09E-03	1.02E-02	3.97E+00	7.23E-05
# Cells	0-180	4.72E-05	3.32E-05	6.11E-05	1.73E+00	8.39E-02
	180-360	5.16E-05	3.65E-05	6.66E-05	1.65E+00	9.90E-02
	360-540	-4.94E-06	-3.29E-05	2.31E-05	-1.32E-01	8.95E-01
	540-720	7.06E-05	4.95E-05	9.17E-05	2.49E+00	1.28E-02
	720-900	-1.07E-04	-2.38E-04	2.33E-05	-1.41E+00	1.58E-01
	>900	2.03E-04	1.43E-04	2.63E-04	1.58E+00	1.14E-01
Eccentricity	0-180	4.30E+00	1.89E+00	6.70E+00	8.73E-01	3.83E-01
	180-360	-1.60E+00	-3.89E+00	6.87E-01	-5.49E-01	5.83E-01
	360-540	3.97E+00	4.59E-01	7.47E+00	4.50E-01	6.53E-01
	540-720	1.72E+01	1.12E+01	2.31E+01	1.15E+00	2.49E-01
	720-900	6.20E+00	-2.94E+00	1.53E+01	3.73E-01	7.09E-01
	>900	5.72E+00	-1.11E+00	1.25E+01	4.22E-01	6.73E-01
# Isolated	0-180	1.21E-04	-1.75E-04	4.17E-04	3.89E-01	6.98E-01
Atypical Cells	180-360	4.85E-04	1.04E-04	8.67E-04	8.19E-01	4.13E-01
	360-540	2.02E-03	1.60E-03	2.44E-03	3.47E+00	5.22E-04
	540-720	1.15E-04	-2.23E-03	2.46E-03	2.37E-02	9.81E-01
	720-900	-4.80E-03	-9.49E-03	-1.21E-04	-7.92E-01	4.29E-01
	>900	2.19E-03	1.24E-04	4.25E-03	5.51E-01	5.82E-01
# Isolated Cells	0-180	3.20E-04	-3.19E-04	9.60E-04	3.78E-01	7.05E-01
High NC	180-360	2.70E-03	1.86E-03	3.54E-03	3.79E+00	1.51E-04
	360-540	2.33E-03	1.48E-03	3.18E-03	1.19E+00	2.34E-01
	540-720	4.15E-03	2.00E-03	6.30E-03	1.24E+00	2.13E-01
	720-900	-2.49E-03	-7.73E-03	2.75E-03	-6.05E-01	5.45E-01
	>900	1.43E-02	1.09E-02	1.77E-02	2.95E+00	3.15E-03
# Dense	0-180	2.85E-04	-5.81E-04	1.15E-03	2.38E-01	8.12E-01
Clusters	180-360	2.08E-03	1.54E-03	2.61E-03	4.87E+00	1.12E-06
	360-540	9.12E-03	7.59E-03	1.06E-02	4.20E+00	2.64E-05
	540-720	-1.02E-02	-1.91E-02	-1.20E-03	-9.38E-01	3.48E-01
	720-900	-4.12E-03	-1.39E-02	5.63E-03	-3.27E-01	7.44E-01
	>900	-3.12E-03	-1.12E-02	4.96E-03	-2.68E-01	7.89E-01

# Clusters	0-180	8.60E-05	5.55E-05	1.16E-04	1.56E+00	1.20E-01
	180-360	1.39E-04	1.10E-04	1.69E-04	3.66E+00	2.50E-04
	360-540	4.19E-05	-9.12E-06	9.29E-05	4.55E-01	6.49E-01
	540-720	4.93E-05	-1.16E-05	1.10E-04	4.64E-01	6.43E-01
	720-900	-5.40E-04	-8.79E-04	-2.02E-04	-1.85E+00	6.48E-02
	>900	5.93E-05	-2.11E-05	1.40E-04	3.87E-01	6.99E-01
% Clusters	0-180	8.25E+00	5.08E+00	1.14E+01	1.93E+00	5.30E-02
Dense/Atypical	180-360	5.06E+00	-2.06E+00	1.22E+01	3.65E-01	7.15E-01
	360-540	2.56E+01	1.99E+01	3.14E+01	2.64E+00	8.39E-03
	540-720	-2.20E+01	-4.32E+01	-7.23E-01	-6.85E-01	4.93E-01
	720-900	3.74E+01	2.15E+01	5.34E+01	1.67E+00	9.44E-02
	>900	2.29E+01	7.72E+00	3.81E+01	1.02E+00	3.07E-01
# Atypical	0-180	7.07E-04	2.25E-04	1.19E-03	1.39E+00	1.65E-01
Clusters	180-360	2.89E-03	1.76E-03	4.02E-03	1.53E+00	1.26E-01
	360-540	3.58E-03	2.71E-03	4.45E-03	2.12E+00	3.40E-02
	540-720	3.22E-03	-5.21E-04	6.96E-03	3.99E-01	6.90E-01
	720-900	-6.12E-03	-1.40E-02	1.74E-03	-5.87E-01	5.57E-01
	>900	4.81E-03	9.55E-04	8.67E-03	6.08E-01	5.43E-01
ABS	0-180	2.74E+00	2.17E+00	3.31E+00	3.00E+00	2.69E-03
	180-360	2.22E+00	1.57E+00	2.86E+00	1.72E+00	8.51E-02
	360-540	-1.86E-01	-1.22E+00	8.45E-01	-1.30E-01	8.96E-01
	540-720	8.28E-01	-5.97E-01	2.25E+00	2.75E-01	7.84E-01
	720-900	2.39E+00	6.42E-01	4.15E+00	9.43E-01	3.46E-01
	>900	7.96E+00	6.45E+00	9.47E+00	3.31E+00	9.41E-04
UC Class	0-180	1.61E+00	1.35E+00	1.88E+00	3.10E+00	1.96E-03
	180-360	8.31E-01	5.37E-01	1.13E+00	1.38E+00	1.68E-01
	360-540	-2.07E-01	-7.32E-01	3.19E-01	-2.03E-01	8.39E-01
	540-720	4.70E-01	-7.19E-02	1.01E+00	4.38E-01	6.61E-01
	720-900	1.29E+00	6.80E-01	1.91E+00	1.39E+00	1.64E-01
	>900	1.49E+00	1.00E+00	1.98E+00	1.55E+00	1.21E-01

811

## 812 Supplementary Table 6: Results from beta regression models comparing recurrence risk to

813 **ABS scores during distinct time periods**; Coefficients **B** represents differences in ABS scores

814 between low and high risk patients at specific time periods; the final coefficient represents how

815 ABS scores are changing over time between the first and second recurrences

816

Comparison	<b>Time Period</b>	В	2.5% CI	97.5%	p-value
				CI	
High vs low risk, days since positive primary	0-113	-0.297	-1.169	0.575	0.506
	114-204	0.134	-1.212	1.479	0.846
	205-295	-0.806	-1.849	0.238	0.133
	295-412	-1.038	-1.888	-0.187	0.019
	413-690	-1.186	-1.957	-0.416	0.003
High vs low risk, days until first	>752	-0.070	-0.645	0.505	0.812
recurrence	752-391	0.122	-0.438	0.683	0.669
	390-227	-0.496	-1.086	0.095	0.102
	226-114	0.093	-0.459	0.645	0.742
	113-0	-0.595	-1.193	0.003	0.053
Days until second recurrence, starting from first recurrence	Time in days (continuous)	0.001	0.000	0.001	0.018